Taofeek Owonikoko

Taofeek Owonikoko is a thoracic oncologist and SCLC clinical trials expert who has led or participated in pivotal studies of novel agents including lurbinectedin, trilaciclib, and DLL3-directed bispecific antibodies such as AMG 757 (tarlatamab). His research has contributed to the FDA approvals of lurbinectedin for platinum-refractory SCLC and trilaciclib as myeloprotection during chemotherapy. He investigates biological predictors of treatment response in SCLC and has led NCI-CTEP trials. His contributions span drug development, resistance mechanisms, and translational biomarker research in SCLC.